Logo

Immunophotonics Signs a Research Agreement with Clinical Laserthermia Clinical Laserthermia Systems for Cancer Patients with Solid Tumors

Share this

Immunophotonics Signs a Research Agreement with Clinical Laserthermia Clinical Laserthermia Systems for Cancer Patients with Solid Tumors

Shots:

  • Immunophotonics and CLS collaborate to evaluate the safety & tolerability of Immunophotonics’ IP-001 in P-Ib/IIa study for cancer patients with solid tumors
  • The collaboration will combine CLS’ Immunostimulating Interstitial Laser Thermotherapy (imILT) method & TRANBERG Laser Thermal Therapy System with an intra-tumoral injection of IP-001  
  • Immunophotonics’ IP-001 is designed to be injected intratumorally followed by an interventional oncology procedure i.e- tumor ablation- inducing a polyclonal T cell response against the cancer

Ref: GlobeNewsWire | Image: Medicon Village

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions